Stage iv non-small cell lung cancer Trials in San Antonio, United States
Conditions / Stage iv non-small cell lung cancer / San Antonio, United States
Stage iv non-small cell lung cancer is a medical condition with active clinical research programs worldwide.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00955305 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | TERMINATED | PHASE2 |
| NCT00029003 | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | COMPLETED | PHASE2 |
| NCT00368992 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | COMPLETED | PHASE2 |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | TERMINATED | PHASE1 |
| NCT00087412 | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer | COMPLETED | PHASE2 |
| NCT02438722 | S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | COMPLETED | PHASE1/PHASE2 |
| NCT03137771 | Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT00075751 | Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer | COMPLETED | PHASE2 |
| NCT00068497 | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer | COMPLETED | NA |